Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 13/20 | 0.59 |
| ▸ | DAO | P14920 | 1/20 | 0.53 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.47 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.46 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.45 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1574005 | 0.77 | DAO (0.65) | RIPK1DAOCCNB2CDK1CCNB1 | |
| SCHEMBL27680363 | 0.75 | DAO (0.62) | RIPK1DAOCCNB2CDK1CCNB1 | |
| SCHEMBL575029 | 0.75 | DAO (0.53) | RIPK1DAOCCNB2CDK1CCNB1 | |
| SCHEMBL1176828 | 0.75 | DAO (0.53) | RIPK1DAOCCNB2CDK1CCNB1 | |
| SCHEMBL2595303 | 0.75 | DAO (0.53) | RIPK1DAOCCNB2CDK1CCNB1 | |
| SCHEMBL27984199 | 0.75 | DAO (0.53) | RIPK1DAOCCNB2CDK1CCNB1 | |
| SCHEMBL745278 | 0.75 | DAO (0.53) | RIPK1DAOCCNB2CDK1CCNB1 | |
| SCHEMBL30678374 | 0.75 | DAO (0.62) | RIPK1DAOCCNB2CDK1CCNB1 | |
| SCHEMBL12333 | 0.75 | DAO (0.53) | RIPK1DAOCCNB2CDK1CCNB1 | |
| SCHEMBL20098707 | 0.75 | DAO (0.53) | RIPK1DAOCCNB2CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118724900-B | 4-Amino-7-azaindole compound, preparation method and application thereof | 浙江大学智能创新药物研究院 | 2025-01-28 | — | — | CN | claimed |
| CN-110669058-A | Tricyclic quinolone carboxylic acid and preparation method thereof | 江西农业大学 | 2020-01-10 | — | — | CN | claimed |
| EP-4340833-B1 | NOVEL AZAINDOLE DERIVATIVES AS ANTIVIRAL AGENTS | CENTRE NAT RECH SCIENT (FR) | 2025-09-03 | — | — | EP | disclosed |
| EP-4340839-B1 | NOVEL AZAINDOLE DERIVATIVES AS ANTIVIRAL AGENTS | CENTRE NAT RECH SCIENT (FR) | 2025-02-12 | — | — | EP | disclosed |
| US-20240293400-A1 | NOVEL AZAINDOLE DERIVATIVES AS ANTIVIRAL AGENTS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2024-09-05 | — | — | US | disclosed |
| US-20240239795-A1 | NOVEL AZAINDOLE DERIVATIVES AS ANTIVIRAL AGENTS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2024-07-18 | — | — | US | disclosed |
| EP-4340839-A1 | NOVEL AZAINDOLE DERIVATIVES AS ANTIVIRAL AGENTS | Centre National de la Recherche Scientifique (CNRS) (FR) | 2024-03-27 | — | — | EP | disclosed |
| EP-4340833-A1 | NOVEL AZAINDOLE DERIVATIVES AS ANTIVIRAL AGENTS | Centre National de la Recherche Scientifique (CNRS) (FR) | 2024-03-27 | — | — | EP | disclosed |
| WO-2024041586-A1 | PRODRUG OF JAK KINASE INHIBITOR | 启元生物(杭州)有限公司 | 2024-02-29 | — | — | WO | disclosed |
| WO-2023072301-A1 | PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE COMPOUND AND MEDICAL USE THEREOF | 正大天晴药业集团股份有限公司 | 2023-05-04 | — | — | WO | disclosed |
| WO-2022243650-A1 | NOVEL AZAINDOLE DERIVATIVES AS ANTIVIRAL AGENTS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2022-11-24 | — | — | WO | disclosed |
| US-6025366-A | Antagonists of gonadotropin releasing hormone | MERCK & CO., INC. (US) | 2000-02-15 | — | — | US | disclosed |
| US-5998432-A | SEXUAL DISORDERS | MERCK & CO., INC. (US) | 1999-12-07 | — | — | US | disclosed |
| US-5985892-A | USEFUL FOR THE TREATMENT OF A VARIETY OF SEX-HORMONE RELATED AND OTHER CONDITIONS IN BOTH MEN AND WOMEN; PREVENTING PREGNANCY; TREATING LUPUS ERYTHEMATOSIS, IRRITABLE BOWEL SYNDROME, PREMENSTRUAL SYNDROME, HIRSUTISM, SHORT STATURE OR A | MERCK & CO., LTD. (US) | 1999-11-16 | — | — | US | disclosed |
| WO-1999051234-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 1999-10-14 | — | — | WO | disclosed |
| WO-1999051232-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 1999-10-14 | — | — | WO | disclosed |
| WO-1999051233-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 1999-10-14 | — | — | WO | disclosed |
| WO-1999051596-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 1999-10-14 | — | — | WO | disclosed |
| WO-1999051231-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 1999-10-14 | — | — | WO | disclosed |
| WO-1999051595-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 1999-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240293400-A1 | NOVEL AZAINDOLE DERIVATIVES AS ANTIVIRAL AGENTS | AXL, ZC3HAV1, MERTK | RIPK1 76/4885DAO 1760/4885AOC3 3160/4885 |
| US-20240239795-A1 | NOVEL AZAINDOLE DERIVATIVES AS ANTIVIRAL AGENTS | AXL, ABL1, ZC3HAV1 | RIPK1 85/4885DAO 1801/4885AOC3 3158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.